Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
作者： Simon Pernot , Olivier Dubreuil , Thomas Aparicio , Karine Le Malicot , David Tougeron
DOI: 10.1038/S41416-018-0133-7
关键词:
摘要: Triplet chemotherapy, with docetaxel-5FU-oxaliplatin (TEFOX), has yielded promising results in patients advanced and operable gastric adenocarcinoma. This may prove useful treating signet ring cell carcinoma (SRCC), which is known to be chemoresistant a poor prognosis. We therefore evaluated TEFOX untreated SRCC. Patients metastatic or locally non-resectable SRCC were treated TEFOX. Chemotherapy was administered every 14 days, combined docetaxel (50 mg/m2) oxaliplatin (85 mg/m2) followed by 5FU (2400 mg/m2). Among 65 enrolled, including 17 linitis plastica, ORR DCR 66.1% 87.6%, respectively. Median PFS OS 9.7 months (95% CI [6.9–11.4]) 14.3 [11.6–21.6]) Twenty-six (40%) initially considered as unresectable had secondary resection (n = 24) radiotherapy (n = 2) curative intent, median of 12.4 26.2 months, appears effective first-line treatment an acceptable safety profile. It allowed intent approach 40% patients. Considering the low chemosensitivity reported other chemotherapy regimens pending for randomised studies, might option
nature.com
sci-hub.se 参考文章(28)
Yutaka Yonemura, Takashi Fujimura, Genichi Nishimura, Raul Falla, Toshiharu Sawa, Kanji Katayama, Kouichirou Tsugawa, Sachio Fushida, Itsuo Miyazaki, Motohiro Tanaka, Yoshio Endou, Takuma Sasaki, Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination Surgery. ,vol. 119, pp. 437- 444 ,(1996) , 10.1016/S0039-6060(96)80145-0
Mithat Gonen, Manish A. Shah, Murray F. Brennan, Daniel G. Coit, Vivian E. Strong, Zubin M. Bamboat, Laura H. Tang, Eduardo Vinuela, Deborah Kuk, Stage-Stratified Prognosis of Signet Ring Cell Histology in Patients Undergoing Curative Resection for Gastric Adenocarcinoma Annals of Surgical Oncology. ,vol. 21, pp. 1678- 1685 ,(2014) , 10.1245/S10434-013-3466-8
Li Chen, Yan Shi, Jing Yuan, Qian Wu, Yalin Han, Rui Qin, Baoqing Jia, Bo Wei, Lixin Wei, Guanghai Dai, Shunchang Jiao, Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients. Medical Oncology. ,vol. 31, pp. 159- ,(2014) , 10.1007/S12032-014-0159-5
Simon Pernot, Emmanuel Mitry, Emmanuelle Samalin, Laetitia Dahan, Cécile Dalban, Marc Ychou, Jean-François Seitz, Hajer Turki, Thibault Mazard, Aziz Zaanan, Céline Lepère, Jean-Nicolas Vaillant, Bruno Landi, Philippe Rougier, Julien Taieb, Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer. ,vol. 17, pp. 341- 347 ,(2014) , 10.1007/S10120-013-0266-6
Ph Rougier, M Ducreux, M Mahjoubi, JP Pignon, S Bellefqih, J Oliveira, C Bognel, PH Lasser, M Ychou, D Elias, E Cvitkovic, JP Armand, J-P Droz, None, Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. European Journal of Cancer. ,vol. 30, pp. 1263- 1269 ,(1994) , 10.1016/0959-8049(94)90170-8
O Glehen, V Schreiber, E Cotte, AC Sayag-Beaujard, D Osinsky, G Freyer, Y François, J Vignal, FN Gilly, Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis Arising From Gastric Cancer Archives of Surgery. ,vol. 139, pp. 20- 26 ,(2004) , 10.1001/ARCHSURG.139.1.20
Olivier Glehen, François Noel Gilly, Catherine Arvieux, Eddy Cotte, Florent Boutitie, Baudouin Mansvelt, Jean Marc Bereder, Gérard Lorimier, François Quenet, Dominique Elias, Association Française de Chirurgie, None, Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy Annals of Surgical Oncology. ,vol. 17, pp. 2370- 2377 ,(2010) , 10.1245/S10434-010-1039-7
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile, Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang, None, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial The Lancet. ,vol. 376, pp. 687- 697 ,(2010) , 10.1016/S0140-6736(10)61121-X
Ulrike Heger, Susanne Blank, Christiane Wiecha, Rupert Langer, Wilko Weichert, Florian Lordick, Thomas Bruckner, Martin Dobritz, Maria Burian, Christoph Springfeld, Lars Grenacher, Jörg-Rüdiger Siewert, Markus Büchler, Katja Ott, Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach Annals of Surgical Oncology. ,vol. 21, pp. 1739- 1748 ,(2014) , 10.1245/S10434-013-3462-Z
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira Dos Santos, Giuseppe Aprile, David R Ferry, Bohuslav Melichar, Mustapha Tehfe, Eldar Topuzov, John Raymond Zalcberg, Ian Chau, William Campbell, Choondal Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M Liepa, Ling Gao, Jonathan D Schwartz, Josep Tabernero, None, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet. ,vol. 383, pp. 31- 39 ,(2014) , 10.1016/S0140-6736(13)61719-5